<DOC>
	<DOC>NCT00665561</DOC>
	<brief_summary>The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.</brief_summary>
	<brief_title>Prospective Observational Epidemiologic Study of Maraviroc's Safety</brief_title>
	<detailed_description>All patients meeting the study eligibility criteria at participating sites will be invited to participate.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Treatment experienced, HIV1 infected patients 18 years or older Receive an approved assay for determination of HIV1 tropism Pregnant or lactating Using CCR5 inhibitor other than maraviroc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Maraviroc</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Safety</keyword>
	<keyword>Non-interventional</keyword>
</DOC>